Therapy Areas: AIDS & HIV
Perrigo Company plc wins FDA approval for OTC use of Nasonex 24HR Allergy
18 March 2022 -

Health and wellness company Perrigo Company plc (NYSE:PRGO) reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).

This approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex to enter the OTC marketplace.

Perrigo expects to begin offering Nasonex 24HR Allergy later this year.

Mometasone furoate, is a steroid medication used to treat certain skin conditions, hay fever and asthma.



Related Headlines